Pim-1, 2 and 3 (EC make up a distinct and highly homologous family of serine/threonine kinases belonging to the Ca2+/calmodulin-dependent protein kinase-related (CAMK) family. Pim proteins are widely expressed with high levels in hematopoietic tissue and are aberrantly expressed in a variety of human malignancies. These proteins are considered to be constitutively active and, therefore, regulated by expression and proteosomal degradation. Gene transcription is initiated by a wide range of cytokines, mitogens and growth factors that transduce signals via the Janus kinase-signal transducers and regulators of transcription (JAK/STAT pathway), thereby regulating Pim expression[1]. Pim kinases play a major role in cell cycle regulation, anti-apoptotic activity and the homing and migration of receptor tyrosine kinases mediated via the JAK/STAT pathway. The discovery of these kinases being up-regulated in many hematological malignancies and solid tumors affords them therapeutic opportunities in oncology[2].

[1] Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities. C. Blanco-Aparicioa, A. Carnero. Biochem. Pharm. 2013, 85, 629–643.
[2] Pim kinase inhibitors: a survey of the patent literature. T. Morwick. Expert Opin. Ther. Pat. 2010, 20, 193-212.

4 Item(s)

per page
Axon ID Name Description From price
2795 AZD1208 Pim kinase inhibitor €70.00
2305 CX 6258 hydrochloride Pim kinase inhibitor €99.00
1633 SGI 1776 free base Pim kinase inhibitor €95.00
1923 SMI 4a ATP-competitive and selective inhibitor of Pim kinases €75.00

4 Item(s)

per page
Please wait...